Literature DB >> 19245725

Effectiveness and safety of hypertonic saline inhalation combined with exercise training in patients with chronic obstructive pulmonary disease: a randomized trial.

Silvia R Valderramas1, Alvaro Nagib Atallah.   

Abstract

BACKGROUND: Inhaled hypertonic saline is used for bronchial challenge and sputum induction in patients with chronic obstructive pulmonary disease (COPD). We studied the effects of saline aerosol inhalation before each exercise session in an 8-week pulmonary rehabilitation program.
METHODS: This was a double-blind randomized parallel controlled trial, conducted at an out-patient clinic. Sixty-eight subjects with COPD (mean age 67 +/- 6.5 y, percent of predicted FEV(1) 47 +/- 21) were randomized to inhale either 3% hypertonic saline (34 subjects) or normal saline (34 subjects) before each exercise session in an 8-week exercise program that had 3 sessions per week. We measured 6-min walk distance, dyspnea, and quality of life (with the Medical Outcomes Study 36-item short-form health survey).
RESULTS: After the 8-week exercise program, both groups' mean 6-min walk distance had significantly increased: from 195 +/- 92 m to 251 +/- 97 m (P < .001) in the hypertonic-saline group, and from 237 +/- 93 m to 441 +/- 121 m in the normal-saline group (P < .001). The normal-saline group had greater improvement than the hypertonic-saline group (P < .001). Dyspnea score improved from 3.1 +/- 0.9 to 2.3 +/- 0.8 (P < .01) in the hypertonic-saline group, and from 3.5 +/- 0.2 to 2.3 +/- 1.0 (P < .01) in the normal-saline group. Quality of life also significantly improved, except for the physical-functioning and social aspect domains in the hypertonic-saline group. Adverse effects (cough or bronchospasm) occurred in 4 patients (12%) in the hypertonic-saline group.
CONCLUSIONS: The improvement in 6-min walk distance was greater with normal saline than with hypertonic saline. Hypertonic saline was associated with adverse effects. It is unclear whether the only predictor of improved functional exercise capacity was exercise training. (ClinicalTrials.gov number, NCT00639236.).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19245725

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  12 in total

1.  Chronic Bronchitis: Where Are We Now?

Authors:  Yaniv Dotan; Jennifer Y So; Victor Kim
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04-09

Review 2.  Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.

Authors:  S Vamsee Raju; George M Solomon; Mark T Dransfield; Steven M Rowe
Journal:  Clin Chest Med       Date:  2015-12-24       Impact factor: 2.878

3.  A modified nebulization modality versus classical ultrasonic nebulization and oxygen-driven nebulization in facilitating airway clearance in patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial.

Authors:  Qiaoling Luo; Zeguang Zheng; Huihong Cen; Mei Jiang; Qin Chen
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

4.  Hypertonic Saline Primes Activation of the p53-p21 Signaling Axis in Human Small Airway Epithelial Cells That Prevents Inflammation Induced by Pro-inflammatory Cytokines.

Authors:  Fabia Gamboni; Cameron Anderson; Sanchayita Mitra; Julie A Reisz; Travis Nemkov; Monika Dzieciatkowska; Kenneth L Jones; Kirk C Hansen; Angelo D'Alessandro; Anirban Banerjee
Journal:  J Proteome Res       Date:  2016-08-29       Impact factor: 4.466

Review 5.  Chronic bronchitis and chronic obstructive pulmonary disease.

Authors:  Victor Kim; Gerard J Criner
Journal:  Am J Respir Crit Care Med       Date:  2012-11-29       Impact factor: 21.405

Review 6.  Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease.

Authors:  Pan-Wen Tian; Fu-Qiang Wen
Journal:  J Transl Int Med       Date:  2015-09-30

Review 7.  Effect of "add-on" interventions on exercise training in individuals with COPD: a systematic review.

Authors:  Carlos A Camillo; Christian R Osadnik; Hans van Remoortel; Chris Burtin; Wim Janssens; Thierry Troosters
Journal:  ERJ Open Res       Date:  2016-03-29

Review 8.  Recent Advances in the Development of Novel Drug Candidates for Regulating the Secretion of Pulmonary Mucus.

Authors:  Xin Li; Fengri Jin; Hyun Jae Lee; Choong Jae Lee
Journal:  Biomol Ther (Seoul)       Date:  2020-07-01       Impact factor: 4.634

Review 9.  Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review.

Authors:  Luis Máiz Carro; Miguel A Martínez-García
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

Review 10.  Clinical issues of mucus accumulation in COPD.

Authors:  Frederick L Ramos; Jason S Krahnke; Victor Kim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.